White Paper Is Actually Branded Promotion, FDA Tells Ipsen
This article was originally published in The Pink Sheet Daily
Warning letter states that when only one drug (Increlex in this case) provides a therapy discussed in promotional materials, they "effectively promote" the drug even if they do not mention it by name.
You may also be interested in...
Celgene says the white paper – which FDA says promotes Abaxane as effective for unapproved uses and superior to Bristol-Myers Squibb’s Taxol – was intended solely for potential business partners interested in nab technology.
French drug maker takes control of Tercica, Vernalis’ U.S. subsidiary and Octagen’s investigational hemophilia drug OB-1.
Insmed will no longer provide iPlex growth hormone to short stature patients but can pursue development of the drug in certain other indications.